Mart Saarma

Orion Pharma Oy provides contract manufacturing services to the pharmaceutical sector. Its services include sterile, solid forms, liquid forms, semi-solid forms, hormone, and anti-cancer production, primary as well as secondary packaging, and testing. The company is headquartered in Espoo, Finland.

Laurantis Pharma Oy engages in the development of pharmaceutical products. The company was founded in July 2008 and is headquartered in Turku, Finland.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium.

Part of Amrop International, Hever Group is a British company that provides headhunting services. The company is based in London, UK. Hever Group was acquired by Amrop International on June 15, 2000.

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Lundbeck Ltd. engages in the research, development, production, marketing and sale of pharmaceuticals. It provides services that aid in the treatment of CNS disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy and insomnia. The company was founded in 1972 and is headquartered in St. Albans, the United Kingdom.

The Innovative Medicines Initiative is a public-private partnership that aims to accelerate the development of better and safer medicines for patients. The private company is based in Brussels, Belgium and has subsidiaries in Sweden. The Programme Office, led by the Executive Director, manages the day-to-day operations of the initiative. The initiative recognizes the importance of communication and provides accessible tools generated by their projects to help scientists in their research efforts. The Belgian company was founded by J. Kenneth Charles Knowles.

The Institute for Molecular Medicine Finland engages in research, development, and training in molecular medicines. The private company is based in Helsinki, Finland.

Part of Roche Holding AG, Roche Diagnostics Oy is a Finnish biotechnology company that specializes in in vitro diagnostics. The company is based in Espoo, Finland. RochePRO service provides healthcare professionals with up-to-date information on upcoming events and training, as well as materials for patient care. Roche Diagnostics was founded in 2005. The CEO is Matheus Barbosa Vieira.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Domainex Ltd. operates as a drug discovery company. Its services include drug target expression, structural biology, virtual hit screening, medicinal chemistry, computational chemistry, assay development, and fragment based screening. The firm offers combinatorial domain hunting technology, and leadbuilder virtual hit screening software. The company was founded by Laurence Harris Pearl, Renos Savva, Paul Driscoll and Chrisostosmos Prodromou in 2001 and is headquartered in Saffron Walden, the United Kingdom.

Veraventure Oy is a venture capital investment firm based in Kuopio, Finland. Established in 2003, they are a wholly-owned subsidiary of Finnvera Oy. Veraventure is responsible for the management and development of the parent firm's investments linked to regional funds. Finnvera is a specialized financing firm, owned and operated by the Finnish Government and supervised by the Ministry of Trade and Industry. Veraventure specializes in complementing regional markets in equity financing. They have a particular focus on early-stage financing as well as providing capital related to generational changes and for small and mid-size firms. They are the investment manager of the Seed Fund Vera. The firm also has offices in Oulu and Helsinki, Finland.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

MediSapiens Oy provides solutions for bioinformatics analysis. It offers software and products for biological research. The firm creates customized bioinformatics software solutions to organizations; ranging from data management system, to full sample and data processing system, to an animal deoxyribonucleic acid testing service. Its products include Biond Explorer; Research Integrator; IST Online; Target Scout; and Fusion Scout. The company was founded by Sami Kalevi Kilpinen, Olli-Pekka Kallioniemi, and Tommi Pisto in 2009 and is headquartered in Helsinki, Finland.

Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland.

LZ Therapeutics, Inc. develops novel differentiated products for the treatment of neurological disorders. It provides therapeutics to improve patient outcomes, including improved symptom control and potential disease modification. The company was founded by Jay S. Schneider in 2005 and is headquartered in Chester, PA.

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Desentum Oy operates as a research-based biopharmaceutical firm that specializes in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens. The company was founded by Janne Jänis, Marja-Leena Laukkanen, Pekka Allan Antero Mattila, Merja Niemi, Anja Pallas, Juha Rouvinen, and Kristiina Takkinen in 2011 and is headquartered in Espoo, Finland.

Medix Biochemica Oy Ab develops, produces, and markets monoclonal antibodies, antibody services, and recombinant antigens for in vitro diagnostics industry. It also provides rapid tests for human healthcare. The company was founded in 1985 and is headquartered in Espoo, Finland.

TILT Biotherapeutics Oy is a preclinical stage company working in the field of cancer immunotherapy. It develops genetically modified oncolytic viruses that enhance T-cell therapies for cancer treatment. The company was founded by Akseli Hemminki in 2013 and is headquartered in Helsinki, Finland.